دورية أكاديمية
أعرض في EDS

Pan American League of Associations for Rheumatology Guidelines for the Treatment of Takayasu Arteritis.

التفاصيل البيبلوغرافية
العنوان: Pan American League of Associations for Rheumatology Guidelines for the Treatment of Takayasu Arteritis.
المؤلفون: de Souza AWS; From the Rheumatology Division, Universidad Federal de São Paulo, São Paulo, Brazil., Sato EI; From the Rheumatology Division, Universidad Federal de São Paulo, São Paulo, Brazil., Brance ML; School of Medicine, Rosario National University, Santa Fe, Argentina., Fernández-Ávila DG; Rheumatology Unit, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio. Bogotá, Colombia., Scolnik M; Rheumatology Unit, Hospital, Italiano de Buenos Aires, Buenos Aires, Argentina., Magri SJ; Rheumatology Unit, Hospital Italiano de La Plata, La Plata, Buenos Aires, Argentina., Ugarte-Gil MF; School of Medicine, Universidad Cientifica del Sur, Lima, Peru., Flores-Suárez LF; Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico., Saldarriaga-Rivera LM; Rheumatology Unit, Hospital Universitario San Jorge, Risaralda, Colombia., Babini A; Rheumatology Unit, Hospital Italiano de Cordoba, Cordoba., Zamora NV; Rheumatology Unit, Hospital San Jose, Pergamino, Argentina., Acosta Felquer ML; Rheumatology Unit, Hospital, Italiano de Buenos Aires, Buenos Aires, Argentina., Vergara F; Immunology Unit, Hospital Central, Mendoza, Argentina., Carlevaris L; Rheumatology Unit, Hospital Privado de Mendoza, Godoy Cruz, Argentina., Scarafia S; Rheumatology Unit, Hospital Municipal San Cayetano, Virreyes, Argentina., Soriano Guppy ER; Rheumatology Unit, Hospital, Italiano de Buenos Aires, Buenos Aires, Argentina., Unizony S; Vasculitis and Glomerulonephritis Center, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
المصدر: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases [J Clin Rheumatol] 2023 Oct 01; Vol. 29 (7), pp. 316-325. Date of Electronic Publication: 2023 Aug 09.
نوع المنشور: Systematic Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9518034 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-7355 (Electronic) Linking ISSN: 10761608 NLM ISO Abbreviation: J Clin Rheumatol Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia, PA : Lippincott Williams & Wilkins
Original Publication: Baltimore, MD : Williams & Wilkins, c1995-
مواضيع طبية MeSH: Takayasu Arteritis*/diagnosis , Takayasu Arteritis*/drug therapy , Rheumatology*, Humans ; United States ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Immunosuppressive Agents/therapeutic use ; Methotrexate/therapeutic use
مستخلص: Objective: To develop the first evidence-based Pan American League of Associations for Rheumatology (PANLAR) guidelines for the treatment of Takayasu arteritis (TAK).
Methods: A panel of vasculitis experts developed a series of clinically meaningful questions addressing the treatment of TAK patients in the PICO (population/intervention/comparator/outcome) format. A systematic literature review was performed by a team of methodologists. The evidence quality was assessed according to the GRADE (Grading of Recommendations/Assessment/Development/Evaluation) methodology. The panel of vasculitis experts voted each PICO question and made recommendations, which required ≥70% agreement among the voting members.
Results: Eleven recommendations were developed. Oral glucocorticoids are conditionally recommended for newly diagnosed and relapsing TAK patients. The addition of nontargeted synthetic immunosuppressants (e.g., methotrexate, leflunomide, azathioprine, or mycophenolate mofetil) is recommended for patients with newly diagnosed or relapsing disease that is not organ- or life-threatening. For organ- or life-threatening disease, we conditionally recommend tumor necrosis factor inhibitors (e.g., infliximab or adalimumab) or tocilizumab with consideration for short courses of cyclophosphamide as an alternative in case of restricted access to biologics. For patients relapsing despite nontargeted synthetic immunosuppressants, we conditionally recommend to switch from one nontargeted synthetic immunosuppressant to another or to add tumor necrosis factor inhibitors or tocilizumab. We conditionally recommend low-dose aspirin for patients with involvement of cranial or coronary arteries to prevent ischemic complications. We strongly recommend performing surgical vascular interventions during periods of remission whenever possible.
Conclusion: The first PANLAR treatment guidelines for TAK provide evidence-based guidance for the treatment of TAK patients in Latin American countries.
Competing Interests: D.G.F.-Á. is consultant to Abbvie, Bristol Myers-Squibb, Eli Lilly, Fresenius Kabi, Janssen, Novartis, and Pfizer. M.V.S. is a speaker for and consultant to and receives research support from Abbvie, Bristol Myers-Squibb, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, Roche, and AstraZeneca. S.J.M. is a speaker for and consultant to and receives research support from Abbvie, Boehringer Ingelheim, GlaxoSmithKline, and Janssen. M.F.U.-G. receives research support and consulting fee from and is a speaker for Janssen, Pfizer, AztraZeneca, and GlaxoSmithKline. L.F.F.-S. is a speaker for Nippon Boehringer Ingelheim Co Ltd, Roche México, and Werfen Mexico. L.M.S.-R. is a speaker for and consultant to the advisory board of Novartis, Pfizer, Janssen, Bristol-Myers Squibb, Sanofi-Genzyme, Biopas, Amgen, Boehringer, Roche, and Eli Lilly. A.B. is a speaker and consultant to Abbvie, GlaxoSmithKline, Janssen, Pfizer, Boehringer Ingelheim, and Bristol-Myers Squibb. E.R.S.G. is a speaker for and consultant to and receives research support from Abbvie, Amgen, Bristol Myers-Squibb, Janssen, Eli Lilly, Novartis, Pfizer, Roche, Sandoz, and UCB. S.U. is a consultant to and receives research support from Kiniksa, Janssen, and Genentech. The other authors declare no conflict of interest.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
References: De Souza AW, de Carvalho JF. Diagnostic and classification criteria of Takayasu arteritis. J Autoimmun . 2014;48–49:79–83.
Tomelleri A, Campochiaro C, Sartorelli S, et al. Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. Scand J Rheumatol [Internet] . 2019;48:482–490.
Numano F, Okawara M, Inomata H, et al. Takayasu's arteritis. Lancet . 2000;356:1023–1025.
Watts RA, Hatemi G, Burns JC, et al. Global epidemiology of vasculitis. Nat Rev Rheumatol . 2022;18:22–34.
Onen F, Akkoc N. Epidemiology of Takayasu arteritis. Presse Med . 2017;46(7–8 Pt 2):e197–e203.
Belem JMFM, Pereira RMR, Perez MO, et al. Epidemiologic features of systemic vasculitides in the Southeast Region of Brazil: hospital-based survey. J Clin Rheumatol . 2020;26(7S Suppl 2):S106–S110.
de Souza AWS, Zarur EB, Pimentel-Quiroz VR, et al. Different epidemiologic profiles of systemic vasculitis between Brazil and Peru—preliminary results in two referral centers from both countries. Clin Rheumatol . 2022 Mar 1;41:635–639.
Ochoa CD, Ramírez F, Quintana G, et al. Epidemiología de las vasculitis primarias en Colombia y su relación con lo informado para Latinoamérica. Rev. Colomb. Reumatol . 2009;16:248–263.
Vieira M, Ochtrop MLG, Sztajnbok F, et al. The epidemiology of Takayasu arteritis in Rio de Janeiro, Brazil: a large population-based study. J Clin Rheumatol . 2023. doi: 10.1097/RHU.0000000000001964. (PMID: 10.1097/RHU.0000000000001964)
Barra L, Yang G, Pagnoux C; Canadian Vasculitis Network (CanVasc). Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: a systematic review and meta-analysis. Autoimmun Rev . 2018;17:683–693.
Hoffman GS. Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol . 1996;54 Suppl:S99–S102.
Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford) [Internet] . 2014;53:793–801.
Keser G, Aksu K. What is new in management of Takayasu arteritis? Presse Med . 2017;46(7–8 Pt 2):e229–e235.
Pazzola G, Muratore F, Pipitone N, et al. Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford) . 2018;57:1151–1155.
Pugh D, Karabayas M, Basu N, et al. Large-vessel vasculitis. Nat Rev Dis Primers . 2022;7:93.
Comarmond C, Biard L, Lambert M, et al; French Takayasu Network. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation . 2017;136:1114–1122.
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol [Internet] . 2011;64:383–394.
Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ [Internet] . 2010;182.
Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum . 2007;56:1000–1009.
Soto ME, Espinola N, Flores-Suarez LF, et al. Takayasu arteritis: Clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. Clin Exp Rheumatol . 2008;26(3 Suppl 49):S9–S15.
Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med . 1994;120:919–929.
Bicakcigil M, Aksu K, Kamali S, et al. Takayasu's arteritis in Turkey—clinical and angiographic features of 248 patients. Clin Exp Rheumatol . 2009;27(1 Suppl 52):S59–S64.
Freitas DS, Camargo CZ, Mariz HA, et al. Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int . 2012;32:703–709.
Mutoh T, Shirai T, Fujii H, et al. Insufficient use of corticosteroids without immunosuppressants results in higher relapse rates in Takayasu arteritis. J Rheumatol . 2020;47:255–263.
Ohigashi H, Tamura N, Ebana Y, et al. Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. J Cardiol . 2017;69:774–778.
Palmowski A, Buttgereit F. Reducing the toxicity of long-term glucocorticoid treatment in large vessel vasculitis. Curr Rheumatol Rep [Internet] . 2020;22:85.
Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum . 1994;37:578–582.
Goel R, Danda D, Mathew J, et al. Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol . 2010;29:329–332.
Wu C, Sun Y, Cui X, et al. Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. Ther Adv Chronic Dis . 2020;11:2040622320975233.
Sun Y, Ma L, Ma L, et al. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis. Rheumatol Int . 2017;37:2019–2026.
De Souza AW, da Silva MD, MacHado LS, et al. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol . 2012;41:227–230.
De Souza AW, de Almeida Agustinelli R, de Cinque Almeida H, et al. Leflunomide in Takayasu arteritis—a long term observational study. Rev Bras Reumatol Engl Ed . 2016;56:371–375.
Dai X, Cui X, Sun Y, et al. Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study. Ther Adv Chronic Dis . 2020;11:2040622320922019.
Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol . 2003;30:1793–1798.
Shinjo SK, Pereira RMR, Tizziani VAP, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol . 2007;26:1871–1875.
Li J, Yang Y, Zhao J, et al. The efficacy of mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis. Sci Rep . 2016;6:38687.
Gudbrandsson B, Molberg Ø, Palm Ø. TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study. Arthritis Res Ther . 2017;19:99.
Novikov PI, Smitienko IO, Moiseev SV. Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin Rheumatol . 2013;32:1827–1832.
Campochiaro C, Tomelleri A, Sartorelli S, et al. A prospective observational study on the efficacy and safety of infliximab-biosimilar (CT-P13) in patients with Takayasu arteritis (TAKASIM). Front Med (Lausanne) [Internet] . 2021;8:723506.
Schmidt J, Kermani TA, Bacani AK, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken) . 2012;64:1079–1083.
Molloy ES, Langford CA, Clark TM, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis . 2008;67:1567–1569.
Quartuccio L, Schiavon F, Zuliani F, et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol . 2012;30:922–928.
Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation . 2015;132:1693–1700.
Karageorgaki ZT, Mavragani CP, Papathanasiou MA, et al. Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol . 2007;26:984–987.
Osman M, Pagnoux C, Dryden DM, et al. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. PloS One . 2014;9:e115026.
Hoffman GS, Merkel PA, Brasington RD, et al. Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum . 2004;50:2296–2304.
Comarmond C, Plaisier E, Dahan K, et al. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev . 2012;11:678–684.
Nunes G, Neves FS, Melo FM, et al. Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol . 2010;50:291–298.
Novikov PI, Smitienko IO, Sokolova MV, et al. Certolizumab pegol in the treatment of Takayasu arteritis. Rheumatology (Oxford) . 2018;57:2101–2105.
Kong X, Zhang X, Lv P, et al. Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide. Int J Cardiol . 2018;266:222–228.
Nakaoka Y, Higuchi K, Arita Y, et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J . 2013;54:405–411.
Zhou J, Chen Z, Li J, et al. The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. Clin Exp Rheumatol . 2017;35 Suppl 103:171–175.
Abisror N, Mekinian A, Lavigne C, et al; Club Rhum Inflamm SNFMI. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev . 2013;12:1143–1149.
Goel R, Danda D, Kumar S, et al. Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis. Int J Rheum Dis . 2013;16:754–761.
Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis [Internet] . 2018;77:348–354.
Mekinian A, Biard L, Dagna L, et al. Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology (Oxford) . 2022;61:1376–1384.
Campochiaro C, Tomelleri A, Sartorelli S, et al. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Semin Arthritis Rheum [Internet] . 2020;50:509–514.
Jain S, Kumari S, Ganguly NK, et al. Current status of Takayasu arteritis in India. Int J Cardiol . 1996;54 Suppl:S111–S116.
Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol . 2017;69:846–853.
Mutoh T, Shirai T, Ishii T, et al. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. Nat Commun [Internet] . 2020;11:1253.
Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis . 2012;71:75–79.
Galarza C, Valencia D, Tobón GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol . 2008;34:124–128.
Caltran E, Di Colo G, Ghigliotti G, et al. Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol . 2014;33:1183–1184.
Mutoh T, Ishii T, Shirai T, et al. Refractory Takayasu arteritis successfully treated with rituximab: case-based review. Rheumatol Int . 2019;39:1989–1994.
Ernst D, Greer M, Stoll M, et al. Remission achieved in refractory advanced Takayasu arteritis using rituximab. Case Rep Rheumatol [Internet] . 2012;2012:1–4.
de Souza AWS, Machado NP, Pereira VM, et al. Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J . 2010;74:1236–1241.
Duarte MM, Geraldes R, Sousa R, et al. Stroke and transient ischemic attack in Takayasu's arteritis: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis [Internet] . 2016;25:781–791.
Alibaz-Oner F, Koster MJ, Unal AU, et al. Assessment of the frequency of cardiovascular risk factors in patients with Takayasu's arteritis. Rheumatology (Oxford) . 2017;56:1939–1944.
Kim H, Barra L. Ischemic complications in Takayasu's arteritis: a meta-analysis. Semin Arthritis Rheum . 2018;47:900–906.
Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc [Internet] . 2013;88:822–830.
Vanoli M, Daina E, Salvarani C, et al. Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum [Internet] . 2005;53:100–107.
Labarca C, Makol A, Crowson CS, et al. Retrospective comparison of open versus endovascular procedures for Takayasu arteritis. J Rheumatol [Internet] . 2016;43:427–432.
Park MC, Lee SW, Park YB, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology . 2006;45:600–605.
Wang X, Dang A, Lv N, et al. Long-term outcomes of coronary artery bypass grafting versus percutaneous coronary intervention for Takayasu arteritis patients with coronary artery involvement. Semin Arthritis Rheum . 2017;47:247–252.
Fields CE, Bower TC, Cooper LT, et al. Takayasu's arteritis: operative results and influence of disease activity. J Vasc Surg . 2006;43:64–71.
Mason JC. Takayasu arteritis: surgical interventions. Curr Opin Rheumatol [Internet] . 2015;27:45–52.
Peng M, Ji W, Jiang X, et al. Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis: two-year results. Int J Cardiol . 2016;205:117–123.
Park HS, Do YS, Park KB, et al. Long term results of endovascular treatment in renal arterial stenosis from Takayasu arteritis: angioplasty versus stent placement. Eur J Radiol . 2013;82:1913–1918.
Kim HJ, Lee CS, Kim JS, et al. Outcomes after endovascular treatment of symptomatic patients with Takayasu's arteritis. Interv Neuroradiol . 2011;17:252–260.
Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. J Rheumatol . 2004;31:102–106.
Kinjo H, Kafa A. The results of treatment in renal artery stenosis due to Takayasu disease: comparison between surgery, angioplasty, and stenting. A monocentrique retrospective study. G Chir . 2015;36:161–167.
Song L, Zhang J, Li J, et al. Endovascular stenting vs. extrathoracic surgical bypass for symptomatic subclavian steal syndrome. J Endovasc Ther . 2012;19:44–51.
Saadoun D, Lambert M, Mirault T, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation [Internet] . 2012;125:813–819.
Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J [Internet] . 2014;35:2873–2926.
Matsuura K, Ogino H, Kobayashi J, et al. Surgical treatment of aortic regurgitation due to Takayasu arteritis: long-term morbidity and mortality. Circulation [Internet] . 2005;112:3707–3712.
Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol . 2021;73:1349–1365.
Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis . 2020;79:19–130.
Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum [Internet] . 2010;62:9–21.
Nahata L, Sivaraman V, Quinn GP. Fertility counseling and preservation practices in youth with lupus and vasculitis undergoing gonadotoxic therapy. Fertil Steril [Internet] . 2016;106:1470–1474.
Braga BP, Prieto-González S, Hernández-Rodríguez J. Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases. Med Clin (Barc) [Internet] . 2019;152:502–507.
Keser G, Aksu K, Direskeneli H. Discrepancies between vascular and systemic inflammation in large vessel vasculitis: an important problem revisited. Rheumatology (Oxford) . 2018;57:784–790.
Direskeneli H, Aydin SZ, Merkel PA. Assessment of disease activity and progression in Takayasu's arteritis. Clin Exp Rheumatol . 2011;29(1 Suppl 64):S86–S91.
Fritsch S, Copes RM, Savioli B, et al. Translation and validation of the Indian Takayasu Clinical Activity Score (ITAS2010) for the Brazilian Portuguese language. Adv Rheumatol [Internet] . 2019;59:43.
De Souza AW, de Serrano Lima C, Oliveira ACD, et al. Homocysteine levels in Takayasu arteritis-a risk factor for arterial ischemic events. J Rheumatol . 2013;40:303–308.
Akazawa H, Ikeda U, Yamamoto K, et al. Hypercoagulable state in patients with Takayasu's arteritis. Thromb Haemost . 1996;75:712–716.
Kasuya N, Kishi Y, Isobe M, et al. P-selectin expression, but not GPIIb/IIIa activation, is enhanced in the inflammatory stage of Takayasu's arteritis. Circ J . 2006;70:600–604.
Watanabe T, Kishi Y, Numano F, et al. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis. Thromb Res . 2001;104:77–83.
Seyahi E, Ucgul A, Cebi Olgun D, et al. Aortic and coronary calcifications in Takayasu arteritis. Semin Arthritis Rheum . 2013;43:96–104.
Comparison of adalimumab and tofacitinib in the treatment of active Takayasu arteritis—full text view. ClinicalTrials.gov [Internet] . Available at: https://clinicaltrials.gov/ct2/show/NCT05151848?term=Adalimumab&cond=Takayasu+Arteritis&draw=2&rank=1 . Accessed December 5, 2022.
Comparison of tofacitinib and methotrexate in Takayasu's arteritis—full text view. ClinicalTrials.gov [Internet] . Available at: https://clinicaltrials.gov/ct2/show/NCT05102448?term=05102448&draw=2&rank=1 . Accessed December 5, 2022.
A study of ustekinumab in participants with Takayasu arteritis (TAK)—full text view. ClinicalTrials.gov [Internet] . Available at: https://clinicaltrials.gov/ct2/show/NCT04882072?term=04882072&draw=2&rank=1 . Accessed December 5, 2022.
A study to evaluate the efficacy and safety of upadacitinib in participants with Takayasu arteritis (TAK)—full text view. ClinicalTrials.gov [Internet] . Available at: https://clinicaltrials.gov/ct2/show/NCT04161898?term=04161898&draw=2&rank=1 . Accessed December 5, 2022.
Fernández-Ávila DG, Patino-Hernandez D, Kowalskii S, et al. Current status of the rheumatologists' workforce in Latin America: a PANLAR collaborative study. Clin Rheumatol [Internet] . 2021;40:2913–2920.
المشرفين على المادة: 0 (Tumor Necrosis Factor Inhibitors)
0 (Immunosuppressive Agents)
YL5FZ2Y5U1 (Methotrexate)
تواريخ الأحداث: Date Created: 20230809 Date Completed: 20230927 Latest Revision: 20230927
رمز التحديث: 20240628
DOI: 10.1097/RHU.0000000000002004
PMID: 37553869
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-7355
DOI:10.1097/RHU.0000000000002004